BioVie Inc (NASDAQ:BIVI) said it has made significant progress with its clinical programs, including its drug candidate NE3107 showing a clinically meaningful increase in motor control in patients with Parkinson’s disease who were treated with the drug for 28 days.
In a letter to shareholders, BioVie CEO Cuong Do said over the course of 2022, the company provided positive topline results from its Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) trials.
“Furthermore, we found that NE3107 has an unexpected impact on the biomarkers of aging-related disease states and how this may affect disease progression, which provides additional avenues of exploration for the molecule,” Do said.
READ: BioVie announces positive results from two Phase 2 trials assessing NE3107’s potential in Parkinson’s Disease and Alzheimer’s Disease
Looking ahead to 2023, he said the company would be kicking off its additional data readouts with the presentation of its Parkinson’s data at the AD/PD 2023 International Conference on Alzheimer’s and Parkinson’s Diseases to be held from March 28 to April 1, 2023, in Gothenburg, Sweden.
This will be followed by the data read out from its Phase 2 trial evaluating BIV201 in ascites in the first half of the year, with BioVie anticipating reading out the Phase 3 potentially pivotal trial for NE3107 in AD in 3Q 2023.
“Given the efficacy signal detected in the Parkinson’s Phase 2 trial, we will start planning the next phase of the clinical development program for discussion with the FDA in anticipation of launching Phase 3 for PD trials in 2023 as well,” Do concluded.
The full shareholder letter can be found here.
BioVie is a clinical-stage company developing innovative therapies to overcome unmet medical needs in chronic debilitating conditions.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie